Trial
NCT03119064
BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Brown University
Collaborators
Merrimack Pharmaceuticals; Rhode Island Hospital
Condition
Glioblastoma Multiforme
Intervention
Nanoliposomal Irinotecan
Why stopped
lack of response to study therapy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-13